{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:19:01Z","timestamp":1786119541457,"version":"build-2736575974"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1097\/hco.0b013e32833a8828","type":"journal-article","created":{"date-parts":[[2010,6,2]],"date-time":"2010-06-02T10:54:20Z","timestamp":1275476060000},"page":"355-365","source":"Crossref","is-referenced-by-count":14,"title":["ALLHAT: still providing correct answers after 7 years"],"prefix":"10.1097","volume":"25","author":[{"given":"Paula T","family":"Einhorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry R","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson T","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboob","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K","family":"Whelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara L","family":"Pressel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210204","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"R2-12-20210204","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","article-title":"Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"R3-12-20210204","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.HYP.0000086521.95630.5A","article-title":"Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"42","year":"2003","journal-title":"Hypertension"},{"key":"R4-12-20210204","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"R5-12-20210204","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"R6-12-20210204","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/HYPERTENSIONAHA.108.120154","article-title":"Antihypertensive prescriptions for newly treated patients before and after the main Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial results and Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines","volume":"53","author":"Muntner","year":"2009","journal-title":"Hypertension"},{"key":"R7-12-20210204","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1161\/HYPERTENSIONAHA.108.126169","article-title":"Postgame wrap of the ultimate blood pressure megatrial: did it score an ALLHAT trick or was it \u2018three strikes and you're out?\u2019","volume":"53","author":"Feldman","year":"2009","journal-title":"Hypertension"},{"key":"R8-12-20210204","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1740774509338234","article-title":"Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project","volume":"6","author":"Bartholomew","year":"2009","journal-title":"Clin Trials"},{"key":"R9-12-20210204","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archinternmed.2010.130","article-title":"Impact of the ALLHAT\/JNC7 Dissemination Project on thiazide-type diuretic use","volume":"170","author":"Stafford","year":"2010","journal-title":"Arch Intern Med"},{"key":"R10-12-20210204","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1524-6175.2003.02287.x","article-title":"The ALLHAT report: a case of information and misinformation","volume":"5","author":"Weber","year":"2003","journal-title":"J Clin Hypertens"},{"key":"R11-12-20210204","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-139-9-200311040-00012","article-title":"ALLHAT, or the soft science of the secondary end point","volume":"139","author":"Messerli","year":"2003","journal-title":"Ann Intern Med"},{"key":"R12-12-20210204","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00004872-200302000-00001","article-title":"The ALLHAT trial: a verdict or a challenge?","volume":"21","author":"Zanchetti","year":"2003","journal-title":"J Hypertens"},{"key":"R13-12-20210204","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/bmj.326.7400.1156","article-title":"Information from drug companies and opinion leaders","volume":"326","author":"Liberati","year":"2003","journal-title":"BMJ"},{"key":"R14-12-20210204","doi-asserted-by":"crossref","first-page":"39","DOI":"10.7326\/0003-4819-141-1-200407060-00013","article-title":"ALLHAT: setting the record straight","volume":"141","author":"Davis","year":"2004","journal-title":"Ann Intern Med"},{"key":"R15-12-20210204","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","article-title":"A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly","volume":"348","author":"Wing","year":"2003","journal-title":"N Engl J Med"},{"key":"R16-12-20210204","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"R17-12-20210204","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"Dahlof","year":"2005","journal-title":"Lancet"},{"key":"R18-12-20210204","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"R19-12-20210204","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N Engl J Med"},{"key":"R20-12-20210204","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials","volume":"362","author":"Turnbull","year":"2003","journal-title":"Lancet"},{"key":"R21-12-20210204","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archinte.165.12.1410","article-title":"Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials","volume":"165","author":"Turnbull","year":"2005","journal-title":"Arch Intern Med"},{"key":"R22-12-20210204","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archinte.164.9.969","article-title":"The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","volume":"164","author":"Rahman","year":"2004","journal-title":"Arch Intern Med"},{"key":"R23-12-20210204","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archinte.165.8.936","article-title":"Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs. a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Rahman","year":"2005","journal-title":"Arch Intern Med"},{"key":"R24-12-20210204","doi-asserted-by":"crossref","first-page":"172","DOI":"10.7326\/0003-4819-144-3-200602070-00005","article-title":"Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate","volume":"144","author":"Rahman","year":"2006","journal-title":"Ann Intern Med"},{"key":"R25-12-20210204","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2337\/dc07-1452","article-title":"Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"31","author":"Black","year":"2008","journal-title":"Diabetes Care"},{"key":"R26-12-20210204","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/archinternmed.2007.66","article-title":"Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"168","author":"Wright","year":"2008","journal-title":"Arch Intern Med"},{"key":"R27-12-20210204","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/archinte.165.12.1401","article-title":"Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Whelton","year":"2005","journal-title":"Arch Intern Med"},{"key":"R28-12-20210204","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1524-6175.2004.03216.x","article-title":"Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study","volume":"6","author":"Barzilay","year":"2004","journal-title":"J Clin Hypertens"},{"key":"R29-12-20210204","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/archinte.166.20.2191","article-title":"Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"166","author":"Barzilay","year":"2006","journal-title":"Arch Intern Med"},{"key":"R30-12-20210204","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/jama.293.13.1595","article-title":"Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril","volume":"293","author":"Wright","year":"2005","journal-title":"JAMA"},{"key":"R31-12-20210204","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1161\/CIRCULATIONAHA.105.544031","article-title":"Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","volume":"113","author":"Davis","year":"2006","journal-title":"Circulation"},{"key":"R32-12-20210204","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ahj.2006.10.012","article-title":"The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis","volume":"153","author":"Einhorn","year":"2007","journal-title":"Am Heart J"},{"key":"R33-12-20210204","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1751-7176.2009.00149.x","article-title":"Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome?","volume":"11","author":"Grimm","year":"2009","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R34-12-20210204","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1161\/CIRCULATIONAHA.107.762229","article-title":"Heart failure with preserved and reduced left ventricular ejection fraction in the Antihypertensive And Lipid-Lowering Treatment To Prevent Heart Attack Trial","volume":"118","author":"Davis","year":"2008","journal-title":"Circulation"},{"key":"R35-12-20210204","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ahj.2009.10.001","article-title":"Coronary heart disease in moderately hypercholesterolemic, hypertensive black and nonblack patients randomized to pravastatin versus usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)","volume":"158","author":"Margolis","year":"2009","journal-title":"Am Heart J"},{"key":"R36-12-20210204","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.jacc.2009.08.020","article-title":"Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)","volume":"54","author":"Haywood","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R37-12-20210204","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1751-7176.2008.00015.x","article-title":"Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"10","author":"Cushman","year":"2008","journal-title":"J Clin Hypertens"},{"key":"R38-12-20210204","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/archinternmed.2009.60","article-title":"ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses","volume":"169","author":"Wright","year":"2009","journal-title":"Arch Intern Med"},{"key":"R39-12-20210204","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)90944-Z","article-title":"Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context","volume":"335","author":"Collins","year":"1990","journal-title":"Lancet"},{"key":"R40-12-20210204","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1001\/jama.1979.03300230018021","article-title":"Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension.","volume":"242","year":"1979","journal-title":"JAMA"},{"key":"R41-12-20210204","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.1979.03300230028022","article-title":"Five-year findings of the Hypertension Detection and Follow-Up Program. II. Mortality by race-sex and age.","volume":"242","year":"1979","journal-title":"JAMA"},{"key":"R42-12-20210204","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/jama.1997.03550030052033","article-title":"Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension","volume":"278","author":"Kostis","year":"1997","journal-title":"JAMA"},{"key":"R43-12-20210204","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/0895-7061(96)00037-4","article-title":"Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"9","author":"Davis","year":"1996","journal-title":"Am J Hypertens"},{"key":"R44-12-20210204","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jama.293.13.1663","article-title":"Diuretics are color blind","volume":"293","author":"Neaton","year":"2005","journal-title":"JAMA"},{"key":"R45-12-20210204","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1161\/CIRCOUTCOMES.109.850008","article-title":"National Heart, Lung, and Blood Institute-initiated program \u2018Interventions to Improve Hypertension Control Rates in African Americans\u2019: background and implementation","volume":"2","author":"Einhorn","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R46-12-20210204","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/HYPERTENSIONAHA.108.113357","article-title":"Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988\u20131994 and 1999\u20132004","volume":"52","author":"Cutler","year":"2008","journal-title":"Hypertension"},{"key":"R47-12-20210204","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1525-1497.2000.02349.x","article-title":"Intensive care unit use and mortality in the elderly","volume":"15","author":"Yu","year":"2000","journal-title":"J Gen Internal Med"},{"key":"R48-12-20210204","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1161\/CIRCULATIONAHA.108.815944","article-title":"Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute","volume":"119","author":"Lee","year":"2009","journal-title":"Circulation"},{"key":"R49-12-20210204","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1161\/CIRCHEARTFAILURE.107.743146","article-title":"Death in heart failure: a community perspective","volume":"1","author":"Henkel","year":"2008","journal-title":"Circ Heart Failure"},{"key":"R50-12-20210204","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/eurheartj\/ehp422","article-title":"Atrial fibrillation and long-term prognosis in patients hospitalized for heart failure: results from Heart Failure Survey in Israel (HFSIS)","volume":"31","author":"Shotan","year":"2010","journal-title":"Eur Heart J"},{"key":"R51-12-20210204","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/08037050310031819","article-title":"ALLHAT: a critical assessment","volume":"13","author":"Sjoholm","year":"2004","journal-title":"Blood Press"},{"key":"R52-12-20210204","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00392-004-0096-y","article-title":"Lessons from ALLHAT. Are low budget diuretics first line therapy in hypertension?","volume":"93","author":"Unger","year":"2004","journal-title":"Z Kardiol"},{"key":"R53-12-20210204","first-page":"293","article-title":"The SOLVD Investigators.","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"R54-12-20210204","first-page":"685","article-title":"The SOLVD Investigators.","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"R55-12-20210204","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"R56-12-20210204","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting-enzyme inhibition in stable coronary artery disease","volume":"351","author":"Braunwald","year":"2004","journal-title":"N Engl J Med"},{"key":"R57-12-20210204","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/0003-4819-137-5_Part_1-200209030-00006","article-title":"Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial","volume":"137","author":"Davis","year":"2002","journal-title":"Ann Intern Med"},{"key":"R58-12-20210204","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1751-7176.2009.00166.x","article-title":"The role of chlorthalidone in patients with high-risk hypertension","volume":"11","author":"Pitt","year":"2009","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R59-12-20210204","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1751-7176.2009.00169.x","article-title":"Prevention of heart failure with chlorthalidone in ALLHAT: placing the results into perspective","volume":"11","author":"Massie","year":"2009","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R60-12-20210204","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy","volume":"138","author":"Berl","year":"2003","journal-title":"Ann Intern Med"},{"key":"R61-12-20210204","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"R62-12-20210204","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"R64-12-20210204","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/HJH.0b013e328122dd58","article-title":"Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up","volume":"25","author":"Almgren","year":"2007","journal-title":"J Hypertens"},{"key":"R65-12-20210204","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1161\/HYPERTENSIONAHA.108.114389","article-title":"Thiazide-induced dysglycemia: call for research from a working group from the National Heart, Lung, and Blood Institute","volume":"52","author":"Carter","year":"2008","journal-title":"Hypertension"},{"key":"R66-12-20210204","first-page":"306","article-title":"Hypertension with metabolic syndrome: think thiazides are old hat? ALLHAT says think again","volume":"57","author":"Mendoza","year":"2008","journal-title":"J Fam Pract"},{"key":"R67-12-20210204","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/HJH.0b013e3283298ea2","article-title":"Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension","volume":"27","author":"Zanchetti","year":"2009","journal-title":"J Hypertens"},{"key":"R68-12-20210204","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1056\/NEJMra0907219","article-title":"Use of diuretics in patients with hypertension","volume":"361","author":"Ernst","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/HCO.0b013e32833a8828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:23:55Z","timestamp":1786040635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001573-201007000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/hco.0b013e32833a8828","relation":{},"ISSN":["0268-4705"],"issn-type":[{"value":"0268-4705","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}